In a significant milestone for the Kingdom’s deep tech ecosystem, Amplifai Health has announced the publication of the largest global study evaluating AI-powered thermography for early diabetic foot risk detection. Conducted in collaboration with the Saudi Ministry of Health, the peer-reviewed multicenter study analyzed data from 1,120 individuals across four regions in Saudi Arabia. This achievement underscores the growing capability of Saudi healthtech startups to deliver clinically validated, scalable solutions that address critical healthcare challenges on a global scale.
Validating AI In Real-World Clinical Settings
The study leveraged TFScan, Amplifai Health’s proprietary AI-assisted thermography system, to demonstrate how thermal imaging can identify subtle risk patterns significantly earlier than traditional clinical methods. By using advanced computer vision algorithms, the system segments the foot’s plantar surface to analyze temperature profiles and thermal signatures associated with neuropathy and vascular insufficiency. The results confirmed a strong alignment between thermal abnormalities and clinical markers, proving that the technology can effectively stratify patients based on risk levels in a real-world, non-invasive manner.
Driving Preventative Care And Cost Efficiency
Beyond clinical efficacy, the research highlights the economic impact of early detection. According to Dr. Meshari Alwashmi, CEO of Amplifai Health, the technology enables the identification of the top 10% of patients who are at the highest risk of developing complications. This specific demographic typically drives nearly five times the healthcare costs compared to the rest of the diabetic population. By integrating TFScan into routine primary care workflows, healthcare providers can intervene sooner, preventing severe complications such as amputation while delivering substantial cost savings to the health system.
A Collaborative Ecosystem Triumph
This milestone is a testament to the robust support system surrounding Saudi innovation. The study was supported by the Saudi Ministry of Health and received backing from the KAUST Innovation hub and the National Technology Development Program’s (NTDP) NextEra program. Additional sponsorship came from Taam Health and Tamer Mölnlycke Care. The successful publication, alongside Amplifai’s acquisition of an FDA-approved medical diagnostic device, positions the company as a leader in translating intellectual property into commercially deployed solutions that improve patient outcomes both in the Kingdom and internationally.
About Amplifai Health
Amplifai Health is a Saudi-based health technology company specializing in the application of artificial intelligence and thermography for medical diagnostics. Backed by KAUST and integrated into the Saudi innovation ecosystem, the company focuses on developing non-invasive, scalable digital tools for the early detection of chronic conditions, with a primary focus on preventing diabetic foot complications.
Source: Amplifai Health
